Nov. 2-4: The VEINS
The VEINS (Venous Endovascular INterventional Strategies) is a hands-on, interactive course that focuses on “pulmonary embolism treatment, controversies in VTE management, management of superficial venous disease, and late stage venous disease.”
Monday, Nov. 4, 6:55 a.m., Palmer 1 & 2
Cook will participate in the “Blue Sky Breakfast: The VEINS Innovation Summit.” During this event, Josh Krieger, a Cook engineer, will present on Cook’s future venous innovations such as a percutaneous venous valve.
Nov. 4-7: VIVA
Leading vascular specialists will discuss the latest approaches for the diagnosis and treatment of PVD. This year, there will be an expanded hands-on innovation lab, dedicated pharmacotherapy sessions, a forum on paclitaxel, optimal therapies for patients with CLI, and the latest technology and techniques for the placement and management of AV fistula grafts.
Cook Medical is hosting two symposia that bring together experts to discuss Type B aortic dissection and a global perspective on paclitaxel-coated devices. Cook has also coordinated a pan-industry discussion on how physicians move forward in their practice following the FDA’s guidance on paclitaxel.
Monday, Nov. 4, 12:00-1:15 p.m., Lafite 1
Drs. Joseph Lombardi, Andres Fajardo, and Sukgu Han will speak during a lunch symposium titled “Tackling Type B Aortic Dissection – Hitting the Big Questions. Takeaways from the experts.””
Tuesday, Nov. 5, 12:00-1:15 p.m., Lafite 1
Dr. Michael Dake will serve as moderator of a lunch symposium titled “Paclitaxel and Your Practice: A Global Perspective.”
Panelists will present on the following related topics:
Dr. Dake – “Follow the Data: Zilver PTX Global Data Analysis.”
Dr. Eric Secemsky – “Paclitaxel Device: Real-world evaluations of survival in peripheral vascular revascularization.”
Dr. Thomas Zeller – “Recent Meta-Analysis: How does this impact my daily clinical practice?”
Dr. Osamu Iida – “How is paclitaxel being perceived in Japan?”
Dr. Gary Ansel – “How I had the paclitaxel conversations with my hospital administrator.”
Pan-industry Sponsored Symposium
Thursday, Nov. 7, 12:00-1:15, Margaux
Co-sponsored by: Cook Medical, Bard/BD, Boston Scientific, Philips, Surmodics
Dr. Michael Dake will serve as moderator for a pan-industry lunch symposium titled “Paclitaxel: Where do we go from here?”
Panelists include Drs. Gary Ansel, Joshua Beckman, Daniel Clair, Sean Lyden, Sanjay Misra, Krishna Rocha-Singh, Kenneth Rosenfield, and Eric Secemsky.
“How has the additional vital status data affected the signal?” (Drs. Rocha-Singh and Secemsky)
“FDA HCP Letter: How has it changed: A physician’s perspective and FDA perspective” (Drs. Beckman and Clair)
“How do we define high risk in the PAD population?” (Drs. Ansel and Lyden)
“How has the totality of evidence and the August HCP letter changed informed consent process?” (Drs. Misra and Rosenfield)
The session ends with “Stakeholder Collaboration: How we move forward together.”
Late-Breaking Clinical Trials
Make sure to stop by the VIVA mainstage in the Global Theater on Tuesday, Nov. 5, at 9:13 a.m. to hear Dr. Michael Dake present “No increased long-term all-cause mortality for the paclitaxel-coated Zilver PTX Drug-Eluting Stent compared to uncoated devices.”
Stop by the Cook booth to talk to us about our Vista® Education and Training courses. And, sign up for our physician newsletter for information on business updates; educational resources; events, conferences, and training; news releases; and product information.
Schedule and speakers subject to change.
Drs. Joseph Lombardi, Andres Fajardo, Sukgu Han, Michael Dake, Eric Secemsky, Thomas Zeller, and Osamu Iida are paid consultants of Cook Medical.